Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs

References

• Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(9):1233–38.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the rising study. Mod Rheumatol. 2009;19(5):478–87.
   PubMed Web of Science ®Google Scholar
• Ootomo K, Kurita T, Odani T, Fujieda Y, Kato M, Kon Y, et al. The efficacy of treating according to a dose-escalation infliximab increasing protocol. The practice of Treat to Target (T2T) aimed at the low disease activity (in Japanese). Clin Rheumatol Rel Res. 2012;24:118–24.
   Google Scholar
• Toshihiko H, Yayoi H, Eiko N, Yasufumi K, Hiroshi K, Keiich M. Effectiveness of infliximab dose escalation therapy in patients with rheumatoid arthritis in accordance with a protocol- Possibility of reduction or discontinuation of infliximab after dose escalation therapy in daily clinical practice (in Japanese). Clin Rheumatol Rel Res. 2016;28:260–70.
   Google Scholar
• Daisuke K, Satoshi I, Megumi U, Asami A, Hiroshi O, Hajime I, et al. Effectiveness of infliximab for rheumatoid arthritis with dose escalation and shortened dosing interval. Clin Rheumatol Rel Res. 2017;29:12–21.
   Google Scholar
• Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol. 2002;29:667–77.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–77.
   PubMed Web of Science ®Google Scholar
• Oh K, Ito S, Unno M, Kobayashi D, Azuma C, Abe A, et al. The rate of decrease in the disease activity of rheumatoid arthritis during treatment with adalimumab depends on the dose of methotrexate. Intern Med. 2015;54(9):1035–41.
   PubMed Web of Science ®Google Scholar
• Ito S, Unno M, Kobayashi D, Oh K, Otani H, Abe A, et al. Dose escalation of methotrexate in rheumatoid arthritis patients. J New Rem Clin. 2014;63:1302–15.
   Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–88.
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000;43(1):22–29.
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45(12):1558–65.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Yang S, Chen L, Park GS, Bitman B, Wang B, et al. Predicting low disease activity and remission using early treatment response to antitumor necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis. 2012;71(2):206–12.
   PubMed Web of Science ®Google Scholar
• Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multi-center, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis, and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096–103.
   PubMed Web of Science ®Google Scholar
• Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomized, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–50.
   PubMed Web of Science ®Google Scholar
• Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73(1):86–94.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomized EXXELERATE study. Lancet. 2016;388(10061):2763–74.
   PubMed Web of Science ®Google Scholar
• Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, et al. The effectiveness and medication costs of three anti-tumor necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis. 2007;67(9):1229–34.
   Web of Science ®Google Scholar
• Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22–32.
   PubMed Web of Science ®Google Scholar
• Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, et al. A comparative effectiveness study of adalimumab, etanercept, and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012;71(7):1134–42.
   PubMed Web of Science ®Google Scholar